MA27762A1 - Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs - Google Patents

Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs

Info

Publication number
MA27762A1
MA27762A1 MA28546A MA28546A MA27762A1 MA 27762 A1 MA27762 A1 MA 27762A1 MA 28546 A MA28546 A MA 28546A MA 28546 A MA28546 A MA 28546A MA 27762 A1 MA27762 A1 MA 27762A1
Authority
MA
Morocco
Prior art keywords
treatment
affective disorders
compound
formula
dihydrocarbamazepine
Prior art date
Application number
MA28546A
Other languages
English (en)
Inventor
Ferenc Martenyl
Markus Schmutz
Stefanie Zechner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27762A1 publication Critical patent/MA27762A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La présente invention a trait à un procédé pour le traitement, y compris le traitement d'entretien, de troubles affectifs, comprenant l'administration, notamment chaque 20 à 28 heures, audit sujet d'une quantité thérapeutiquement efficace, notamment un quantité entre environ 500 et environ 3000 mg, d'un composé de formule (I), dans laquelle : R1 représente hydrogène ou alkylcarbonyle en C1-C3 ; à l'utilisation d'un composé de formule (I) ou un de ses sels pharmaceutiquement acceptable pour la fabrication d'une composition pharmaceutique pour le traitement de troubles affectifs ; à une combinaison comprenant : (a) un composé de formule (I) et (b) au moins composé choisi parmi le groupe constitué de lithium, de divalproex, d'antipsychotiques classiques, d'antipsychotiques atypiques, de lamotrigine et de médicaments antidépressifs ; et à l'utilisation d'une telle combinaison pour le traitement de troubles affectifs.
MA28546A 2003-04-02 2005-10-11 Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs MA27762A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45986403P 2003-04-02 2003-04-02

Publications (1)

Publication Number Publication Date
MA27762A1 true MA27762A1 (fr) 2006-02-01

Family

ID=33131906

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28546A MA27762A1 (fr) 2003-04-02 2005-10-11 Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs

Country Status (18)

Country Link
US (1) US20070010508A1 (fr)
EP (1) EP1613329A1 (fr)
JP (1) JP2006522064A (fr)
KR (1) KR20050121235A (fr)
CN (1) CN1767834A (fr)
AU (1) AU2004226827B2 (fr)
BR (1) BRPI0409151A (fr)
CA (1) CA2520828A1 (fr)
IS (1) IS8094A (fr)
MA (1) MA27762A1 (fr)
MX (1) MXPA05010614A (fr)
NO (1) NO20055098L (fr)
NZ (1) NZ542555A (fr)
RU (1) RU2367440C2 (fr)
TN (1) TNSN05246A1 (fr)
TW (1) TW200502222A (fr)
WO (1) WO2004087168A1 (fr)
ZA (1) ZA200507742B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
BRPI0520258A2 (pt) * 2005-05-06 2009-09-15 Portela & Ca Sa uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
EP2380574A1 (fr) * 2005-05-06 2011-10-26 Bial-Portela & CA, S.A. Acétate d'eslicarbazépine et procédés d'utilisation
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
GB2437078A (en) 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US20110059947A1 (en) * 2008-02-13 2011-03-10 Targacept, Inc. Alpha 7 nicotinic agonists and antipsychotics
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN102188432B (zh) * 2011-04-07 2012-05-23 江立富 一种用于防治癫痫的药物
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
CN105492442A (zh) 2013-09-06 2016-04-13 日本曹达株式会社 内型-9-氮杂双环[3.3.1]壬烷-3-醇衍生物的制造方法
EP3064490A1 (fr) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé amélioré pour la préparation d'eslicarbazépine et d'acétate d'eslicarbazépine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DE10036289A1 (de) 2000-07-26 2002-02-07 Bosch Gmbh Robert Elektronisch kommutierte elektrische Maschine, insbesondere Motor
KR20050044396A (ko) * 2001-11-12 2005-05-12 노파르티스 아게 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀

Also Published As

Publication number Publication date
TW200502222A (en) 2005-01-16
IS8094A (is) 2005-10-27
AU2004226827B2 (en) 2008-04-03
RU2367440C2 (ru) 2009-09-20
US20070010508A1 (en) 2007-01-11
RU2005133665A (ru) 2006-06-10
JP2006522064A (ja) 2006-09-28
BRPI0409151A (pt) 2006-03-28
NO20055098D0 (no) 2005-11-01
MXPA05010614A (es) 2005-11-23
KR20050121235A (ko) 2005-12-26
TNSN05246A1 (en) 2007-06-11
NZ542555A (en) 2009-03-31
ZA200507742B (en) 2008-07-30
EP1613329A1 (fr) 2006-01-11
WO2004087168A1 (fr) 2004-10-14
NO20055098L (no) 2005-12-22
CN1767834A (zh) 2006-05-03
AU2004226827A1 (en) 2004-10-14
CA2520828A1 (fr) 2004-10-14

Similar Documents

Publication Publication Date Title
MA27762A1 (fr) Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs
DK1714960T3 (en) NEW THERAPEUTIC MEDICINE FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) OR DISEASE AScribed
AU762128B2 (en) Agents with an antidepressive effect
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
MA29684B1 (fr) Composes de spiro-oxindole et utilisations associees en tant qu&#39;agents therapeutiques
RU2008133654A (ru) Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
US9839627B2 (en) Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
HUP0103781A2 (hu) Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BG102669A (bg) Метод за лечение и фармацевтичен състав
MA46342B1 (fr) Dérivés de chromane, d&#39;isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
US20230285373A1 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
TNSN05054A1 (fr) Precurseur de medicament inhibiteur de beta-lactamase
EP0530311A1 (fr) Utilisation de phenylpropanolamine comme secretagogue muqueux des voies respiratoires superieures
KR100863384B1 (ko) 아고멜라틴과 노르아드레날린 재흡수 억제제 사이의 신규한 회합 및 이를 포함하는 약제학적 조성물
FR2792199A1 (fr) Utilisation de l&#39;osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l&#39;humeur
CA2544136A1 (fr) Utilisation de l&#39;agomelatine pour l&#39;obtention de medicaments destines au traitement des troubles bipolaires
TNSN00015A1 (fr) Nouveaux sels de morpholinobenzamide
US20240156757A1 (en) Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4052702A1 (fr) Inhibiteur cxcl8 et composition pharmaceutique associée pour une utilisation dans le traitement de crises d&#39;épilepsie
CA2658614A1 (fr) Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
KR20040066892A (ko) 치료 방법
CA2166781A1 (fr) Utilisation de l&#39;efaroxan et de ses derives pour la fabrication de medicaments destines au traitement des maladies neurodegeneratives